30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

1Q13 Revenue: Alphatec Spine

$50.4MM, +6% (U.S. $33.1MM, +2%; Ex-U.S. $17.4MM, +16%; Japanese subsidiary +9%; Phygen $2MM)

  • Good reception for Pegasus anchored anterior cervical interbody device
  • Market interest growing for Solus anterior lumbar interbody fusion device
  • PureGen remains on shipping hold, awaiting FDA feedback on company’s response to Form 483 observations
  • Reporting mid-single-digit price pressure
  • In complete agreement with U.S. Office of Inspector General (OIG) that all physician-owned distributors must act in compliance with law; have amended stocking distributor policy to address all OIG concerns
  • Received FDA 510(k) clearance for improved Epicage posterior interbody spacer